How Qnovia aims to use inhaled therapeutics for smoking cessation

Qnovia’s nicotine replacement therapy device. [Image courtesy of Qnovia] Led by a former tobacco company executive, Qnovia looks to offer nicotine replacement therapy through inhaled drug delivery.

Brian Quigley spent just over 16 years at tobacco giant Altria. During his time there, he ran two U.S. business units, including the smokeless tobacco business.

In July 2020, he joined founder and then-CEO at Qnovia (then Respira Technologies) Mario Danek as chief operating officer. Now CEO, with Danek as chief technology officer, Quigley leads the company as it looks to bring a prescription smoking cessation therapy to market.

Quigley acknowledged the potential applications Qnovia could pursue with its inhaled therapeutic technology. For now, though, the focus is firmly on pursuing FDA approval for what would be the first inhalable prescription smoking cessation therapy.

“I joined Qnovia because of what I learned when I first met Mario Danek,” Quigley t…

Read more
  • 0